Artificial Organ and Bionics Market Report 2025

The artificial organ and bionics market size has grown rapidly in recent years. It will grow from $32.82 billion in 2024 to $36.14 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to rising chronic diseases, medical innovation and research, growing acceptance of transplants, government initiatives and funding, improvements in biocompatibility.

The artificial organ and bionics market size is expected to see rapid growth in the next few years. It will grow to $56.71 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increasing healthcare expenditure, personalized medicine, regulatory support and streamlined approvals, rapid advancements in 3d printing, collaborations and partnerships. Major trends in the forecast period include miniaturization and wearable technology, technological advancements, advanced materials integration, ai and machine learning in design, 3d printing and bioprinting advancements.

Increasing healthcare expenditure is anticipated to drive the growth of the artificial organ and bionics market in the future. Healthcare expenditure encompasses the total spending on health care and related activities, including both private and public health insurance, health research, and public health initiatives. Investments in healthcare facilitate technological innovations, leading to the development of more advanced and efficient artificial organs. This may involve enhancements in materials, design, and manufacturing processes. For example, in December 2023, the Centers for Medicare and Medicaid Services, a U.S. federal agency, reported that national health expenditures in the United States grew by 4.3% in 2022, up from a 2.7% increase in 2021. Consequently, rising healthcare expenditure is propelling the artificial organ and bionics market forward.

An increasing number of transplants is projected to drive the growth of the artificial organ and bionics market in the future. A transplant involves the surgical procedure where a tissue or organ is transferred from a donor to a recipient, or from one part of the body to another. Artificial organs are devices implanted in the body to replace damaged organs and replicate their specific functions, enabling patients to lead a normal life. For example, in January 2024, the Organ Procurement and Transplantation Network (OPTN), a U.S.-based organization, reported that in 2023, there were a total of 46,632 organ transplants performed using both living and deceased donors. This marked an 8.7% increase compared to 2022 and a 12.7% rise from 2021, the first year to surpass 40,000 transplants. Among these, 39,679 transplants were from deceased donors, reflecting an 8.9% increase from the previous year and setting a record for the eleventh consecutive year. Thus, the growing number of transplants is expected to significantly boost the artificial organ and bionics market.

Major corporate investments are steering the transformation of organ transplantation within the artificial organs and bionics market. These investments play a pivotal role in fostering the development of artificial organs, addressing the scarcity of donor organs by creating functional and biocompatible replacements. This not only offers hope to patients awaiting organ transplants but also holds the potential to revolutionize the landscape of transplantation medicine. An exemplar is the Government of Canada's investment of $2 million in April 2022 towards innovative organ and tissue donation projects, aimed at enhancing organ donation and transplantation efficacy in Canada. This funding aligns with the Networks of Centres of Excellence Program, dedicated to supporting organ donation and transplantation research.

Leading companies in the artificial organ and bionics market are advancing technologies like hearing devices to enhance connectivity, improve user experiences, and enable seamless integration between various devices. Hearing technology includes devices and solutions aimed at assisting individuals with hearing impairments, such as hearing aids and cochlear implants. For example, in November 2022, Cochlear Limited, an Australia-based medical device company, received approval from the U.S. Food and Drug Administration (FDA) for the Nucleus 8 Sound Processor. This device is designed to offer improved sound quality, enhanced connectivity, and user-friendly features, including compatibility with Bluetooth LE Audio technology. This innovation allows users to connect wirelessly to multiple devices, such as smartphones and televisions, creating a more integrated and streamlined listening experience.

In December 2022, Johnson & Johnson, a prominent healthcare products company based in the US, successfully acquired Abiomed Inc. for an undisclosed sum. This strategic acquisition is poised to expedite Johnson & Johnson's progress in providing cutting-edge medical technologies and advancing its MedTech business on a global scale. Abiomed Inc., also based in the US, operates within the sphere of artificial organs and bionics, making its acquisition a significant move for Johnson & Johnson as it aims to further its presence and innovation within this specialized domain.

Major companies operating in the artificial organ and bionics market include Abiomed Inc., Asahi Kasei Medical Co., Ltd, Baxter, Berlin Heart GmbH, Boston Scientific Corporation, Cyberonics Inc., Ekso Bionics Holdings Inc., Getinge AB, Medtronic PLC, Bornlife Prosthetic and Orthotic Inc., Sonova, LifeNet Health, Terumo Corporation, Nano Retina Ltd, Edwards Lifesciences Corporation, Orthofix Medical Inc, Cochlear Limited, Advanced Bionics AG, Ottobock SE & Co. KGaA, Second Sight Medical Products Inc., iWalk Inc., Jarvik Heart Inc, St. Jude Medical Inc., Harmonic Bionics Inc., Open Bionics, Beta Bionics Inc., Bionic Prosthetics and Orthotics, Mobius Bionics, Touch Bionics Ltd, Phytowelt GreenTechnologies GmbH.

North America was the largest region in the artificial organ and bionics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global artificial organ and bionics market report during the forecast period. The regions covered in the artificial organ and bionics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial organ and bionics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Artificial organs and bionics encompass machines or devices designed to substitute the functions of a deficient or absent human organ, while bionics involves constructing artificial systems mirroring certain characteristics of living organisms. Their primary objective is to enhance an individual's lifespan and functionality.

Within this domain, the main products include artificial organs and artificial bionics. Artificial organs are devices utilized to replicate the functions of missing or impaired human organs or body parts. These can be categorized based on fixation types as either implantable or externally-worn, and further segmented into cardiac bionics and brain bionics. The technologies encompassed within this field encompass mechanical bionics and electronic bionics.

The artificial organ and bionics market research report is one of a series of new reports that provides artificial organ and bionics market statistics, including artificial organ and bionics industry global market size, regional shares, competitors with an artificial organ and bionics market share, detailed artificial organ and bionics market segments, market trends and opportunities, and any further data you may need to thrive in the artificial organ and bionics industry. This artificial organ and bionics market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The artificial organs and bionics market consists of sales of artificial hearts, total artificial hearts (TAH), artificial kidneys, artificial livers, ear bionics, vision bionics, orthopaedic bionics, and heart bionics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.